AB Science SA announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase III study of masitinib in amyotrophic lateral sclerosis (ALS). Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
[AB Science SA]
7992332
{7992332:nan}
apa
50
1
165982
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/